CRL Charles River Laboratories
Data as of close
Industrials · Services-Commercial Physical & Biological Research
Charles River Laboratories (CRL) is an industrial company in the Services-Commercial Physical & Biological Research industry, with a market capitalization of $16.2 billion. Shares last traded at $338.37, 10.8% below their 52-week high. Over the past year the stock is up 88.9%. Net profit margin is -6.0%, below the peer median of 7.4%. Revenue declined 0.9% year over year.
* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.
Performance
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
Financials
Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-06-27. Source: SEC EDGAR/XBRL.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q2 2026 | -$0.03 | 2026-08-05 |
| Q1 2026 | -$0.30 | 2026-05-07 |
| Q4 2025 (derived) | -$5.57 | 2026-02-18 |
| FY 2025 | -$2.91 | 2026-02-18 |
| Q3 2025 | $1.10 | 2025-11-05 |
| Q2 2025 | $1.06 | 2025-08-06 |
Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.
Services-Commercial Physical & Biological Research peers
CRL vs 14 industry peers (Services-Commercial Physical & Biological Research), by market cap. Data as of close
| IQV | IQVIA | $42.6B | 30.55 | 2.46 | 8.1% | -3.34% |
| INCY | Incyte | $24.5B | 60.65 | 4.07 | 6.7% | -0.30% |
| MEDP | Medpace Holdings, Inc. | $18.1B | 35.01 | 6.39 | 18.2% | -0.61% |
| CRL | Charles River Laboratories | $16.2B | — | 4.04 | -6.0% | -5.88% |
| ABSI | Absci Corp | $1.7B | — | 366.58 | — | -12.98% |
| OABI | OmniAb, Inc. | $742M | — | — | — | -0.29% |
| NRC | Nrc Health | $536M | 46.18 | 3.83 | 8.3% | +1.85% |
| MXCT | MAXCYTE, INC. | $148M | — | — | — | -9.78% |
| IBAC | IB Acquisition Corp. | $54M | — | — | — | -0.69% |
| ONMD | OneMedNet Corp | $25M | — | — | — | -0.83% |
| ISPC | iSpecimen Inc. | $2M | — | — | — | -1.14% |
| BIAF | bioAffinity Technologies, Inc. | $2M | — | — | — | +10.34% |
| IBACR | IB Acquisition Corp. | — | — | — | — | -1.06% |
| BIAFW | bioAffinity Technologies, Inc. | — | — | — | — | +6.48% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.